-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $50

Benzinga·11/24/2025 14:42:17
Listen to the news
Barclays analyst Gena Wang maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $81 to $50.